Our in vitro final results counsel that EAM-2201 need to be examined with regards to likely in vivo pharmacokinetic drug–drug interactions a result of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 functions and aggressive inhibition of UGT1A3 action. It appears to display a greater potency in vitro than JWH-018. https://nikosb050ods3.wikihearsay.com/user